During the first respiratory syncytial virus (RSV) season in which a maternal vaccine and a monoclonal antibody for infants ...

The overall uptake of RSV vaccine is low during its first season in those aged 60 years or older in the United States. The ...

Most infants hospitalised for RSV-related infections need oxygen support and critical care despite nirsevimab use, with ...

A recent study revealed that newborns can be easily protected against respiratory syncytial virus infection by using the ...

A meta-analysis indicates that the monoclonal antibody nirsevimab offers significant real-world protection against severe ...

ACIP is recommending that adults aged 50 to 59 years who are at increased risk for severe RSV disease receive a single dose of an RSV vaccine.

Nirsevimab, a monoclonal antibody, is highly effective in real-world conditions at preventing severe respiratory syncytial ...

Saskatchewan is expanding its infant RSV immunization program to include all babies born one month before and during RSV ...

A single-shot therapy offered to newborns in Ireland between September last and the end of February has dramatically reduced ...

The seasonal timing of when infants receive the new respiratory syncytial virus (RSV) immunization is crucial for ensuring ...

Saskatchewan is expanding its infant immunization program to protect all newborns from Respiratory Syncytial Virus (RSV) ...

The U.S. Centers for Disease Control and Prevention (CDC) recommends that all babies be protected from RSV by one of two ...